Astatine-211 stands out among alpha-emitting radionuclides as the only one capable of forming stable covalent carbon-astatine bonds, opening unique therapeutic avenues for cancers that resist conventional approaches. Protheragen delivers comprehensive At-211 radiolabeling solutions—from precursor design and radiochemical synthesis to stability validation and preclinical assessment—tailored to accelerate your targeted alpha therapy pipeline toward clinical translation.
Astatine-211 (At-211) is an alpha-emitting radionuclide with a physical half-life of approximately 7.2 hours and a 100% alpha-emission branching ratio, making it exceptionally suited for targeted alpha therapy (TAT). Unlike metallic alpha-emitters such as actinium-225 or lead-212, At-211 can form direct covalent bonds with carbon, enabling the creation of small-molecule and protein-based radiopharmaceuticals capable of penetrating biological barriers including the blood-brain barrier. Its alpha particles deliver high linear energy transfer (approximately 100 keV/μm) over an extremely short tissue range of 50–100 μm, depositing lethal radiation doses directly to malignant cells while minimizing collateral damage to surrounding healthy tissue. This unique radiobiological profile positions At-211 as a frontline candidate for treating micrometastatic disease and residual tumor cell clusters that evade conventional beta-emitting radioimmunotherapies.
Fig 1. First-in-human SPECT/CT imaging of [²¹¹At]PSMA-5 compared with [¹⁸F]PSMA-1007 PET/CT: (A) PET/CT showing high uptake in prostate primary lesion (red arrow) and left iliac lymph node metastasis (red arrow); (B) SPECT/CT of the same patient demonstrating specific [²¹¹At]PSMA-5 accumulation in corresponding lesions, confirming excellent tumor targeting of At-211-labeled PSMA ligands. (Watabe, Tadashi, et al., 2025)
The radiochemistry of At-211 encompasses both electrophilic and nucleophilic synthetic pathways. Electrophilic approaches—particularly halo-demetallation of stannyl, silyl, or germyl precursors using oxidants such as N-chlorosuccinimide (NCS) or Iodogen—remain the gold standard for producing [211At]astato(hetero)aryl compounds used in ongoing clinical trials. Nucleophilic strategies, including halogen exchange, astatodediazotation, and emerging copper-catalyzed astatodeboronation, offer complementary routes with distinct advantages in molar activity and precursor shelf stability. A persistent challenge across all labeling methods is maintaining the integrity of the carbon-astatine bond under biological conditions; deastatination releases free astatide that accumulates in thyroid and gastric tissues, driving intensive research into stabilization chemistries such as guanidinomethyl functionalization, neopentyl glycol scaffolds, and boron-cluster conjugation.
The global landscape of targeted alpha therapy has shifted from niche academic curiosity to a prioritized industrial pipeline, with At-211 radiopharmaceuticals leading clinical translation across solid tumors and hematologic malignancies. Completed Phase I trials in glioblastoma and ovarian cancer have established proof-of-concept for locoregional and intracavitary administration, demonstrating predominantly Grade I–II toxicities and no dose-limiting events at clinically relevant activity levels. Meanwhile, ongoing investigations in leukemia conditioning, neuroblastoma, and prostate cancer are expanding the therapeutic envelope. Concurrently, the production infrastructure is undergoing rapid decentralization: dedicated α-beam cyclotrons, automated dry-distillation modules, and transportable hot-cell systems are being deployed across North America, Europe, and Asia to overcome the historical supply bottleneck imposed by At-211's short half-life.
| Parameter | Description |
|---|---|
| Physical half-life | ~7.2 hours |
| Alpha emission | 100% branching ratio; single α-particle per decay |
| Tissue range | 50–100 μm (ideal for micrometastases) |
| Linear energy transfer (LET) | ~100 keV/μm (highly cytotoxic) |
| Primary production route | 209Bi(α,2n)211At cyclotron irradiation (~28–29 MeV α-beam) |
| Completed clinical trials | Glioblastoma (Duke, NCT00003461); Ovarian cancer (Gothenburg, NCT04461457) |
| Ongoing clinical trials | AML/MDS conditioning (Seattle, NCT03128034); Neuroblastoma (Philadelphia, planned) |
| Primary targeting vectors | mAbs, F(ab')2 fragments, sdAbs, peptides, small molecules |
| Key radiochemical challenge | In vivo C-At bond stability against oxidative dehalogenation |
| Emerging stabilization strategies | Guanidinomethyl functionalization; closo-decaborate clusters; ortho-functionalized aryl scaffolds; AI-driven molecular design |
| Global production outlook | Dedicated TR-Alpha cyclotrons; LINAC-based production; automated synthesis modules |
Protheragen operates as a full-spectrum radiopharmaceutical CRDMO and CRO, bridging the critical gap between academic radiochemistry discoveries and clinically viable At-211 therapeutics. Our integrated platform encompasses cyclotron-accessible isotope sourcing, GMP-adjacent radiochemistry suites equipped for alpha-emitter handling, and preclinical pharmacology teams with deep expertise in alpha-particle biodistribution, dosimetry, and tumor microenvironment penetration. Whether your program requires proof-of-concept radiolabeling for a novel targeting vector, comprehensive IND-enabling studies conducted under Investigator-Initiated Trial (IIT) frameworks, or scale-up toward first-in-human radiopharmaceutical supply, we engineer each engagement around the unique decay kinetics, radiolytic sensitivity, and stability demands inherent to At-211.
Design and preparation of stannyl, silyl, iodonium, and boronic acid precursors optimized for high radiochemical yield (>70%) and elevated molar activity, with structural modifications to enhance C-At bond stability.
Direct and indirect radiolabeling of monoclonal antibodies, antibody fragments (F(ab')2, Fab'), single-domain antibodies, peptides, and small-molecule ligands via electrophilic destannylation/desilylation or nucleophilic copper-catalyzed routes.
HPLC, ITLC, and SPE-based purity verification; radiochemical yield and molar activity determination; free astatide quantification; and endotoxin screening compliant with radiopharmaceutical release criteria.
Serum stability profiling at 37°C, plasma protein binding evaluation, metabolite analysis under physiologically relevant conditions, and competitive binding assays to confirm preservation of vector affinity post-labeling.
Gamma-camera imaging leveraging Po-211 K X-ray emissions (77–92 keV); tissue dosimetry calculations; tumor-to-normal tissue ratio quantification; and time-resolved pharmacokinetic analysis in xenograft and syngeneic models.
Tumor growth inhibition studies, survival analysis, hematologic toxicity profiling, and organ-at-risk dosimetry in hematologic and solid tumor models, with GLP-consistent documentation for regulatory submission.
Our At-211 radiolabeling workflow is engineered to maximize radiochemical yield while minimizing decay losses within the constrained 7.2-hour half-life window. Each stage integrates real-time quality checks and radiation safety protocols to ensure reproducible, high-purity radiopharmaceutical output suitable for both preclinical research and clinical translation.
Step 1: Precursor Design & Procurement — Computational modeling and multi-step organic synthesis of aryl tin, silicon, boron, or iodonium precursors tailored to your vector's structural and affinity requirements, with shelf-life validation.
Step 2: Isotope Reception & Activation — Dry-distilled or wet-extracted At-211 is received in chemically reactive form; immediate initiation of radiolabeling chemistry preserves maximal specific activity and minimizes radiolytic degradation.
Step 3: Radiolabeling Reaction — Electrophilic destannylation/desilylation or nucleophilic copper-catalyzed astatodeboronation performed under rigorously optimized temperature, solvent, oxidant, and pH conditions to achieve >70% radiochemical yield.
Step 4: Purification & Quality Control — HPLC or SPE purification followed by radiochemical purity assessment (>95% target), molar activity determination, free astatide quantification (<5% threshold), and sterility testing.
Step 5: Bioconjugation (if applicable) — Conjugation of [211At]SAB, [211At]SAGMB, or analogous activated prosthetic groups to lysine ε-amines or engineered cysteine thiols on antibodies, peptides, or other targeting vectors.
Step 6: Stability Validation — In vitro serum stability testing at 37°C over 24–48 hours, and where required, preliminary in vivo biodistribution screening to confirm retention of the C-At bond and vector targeting integrity.
Step 7: Preclinical Study Execution — Pharmacokinetic, efficacy, and toxicity evaluations conducted under GLP-consistent protocols with full chain-of-custody documentation and radiation safety oversight.
Ready to advance your targeted alpha therapy candidate from concept to preclinical or clinical evaluation? Contact our dedicated radiochemistry team today to discuss your At-211 radiolabeling requirements, from initial proof-of-concept studies to comprehensive IND-enabling packages. Reach out to us and let Protheragen be the strategic partner that transforms your alpha-emitter vision into a clinically viable radiopharmaceutical.
Reference